Sunshine Biopharma Inc. Net Income Loss

• Sunshine Biopharma Inc. showed a decrease of -13.9% in Net Income Loss from 2023 to 2024.
• This data is from Sunshine Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2025.
• XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 16 years of available data (2009 to 2024), Sunshine Biopharma Inc.'s Net Income Loss has declined by 689.7%.
• Historical annual values: Fiscal year 2024: -$5.13 million | Fiscal year 2023: -$4.51 million | Fiscal year 2022: -$26.74 million | Fiscal year 2021: -$12.44 million | Fiscal year 2020: -$2.78 million | Fiscal year 2019: -$1.66 million | Fiscal year 2018: -$2.16 million | Fiscal year 2017: -$1.04 million | Fiscal year 2016: -$3.50 million | Fiscal year 2015: -$1.65 million | Fiscal year 2014: -$1.93 million | Fiscal year 2013: -$2.49 million | Fiscal year 2012: -$708.0 thousand | Fiscal year 2011: -$556.2 thousand | Fiscal year 2010: -$537.4 thousand | Fiscal year 2009: -$650.1 thousand.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026